Drugs / Recombinant Human Interleukin-11
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT03720340 Comparator | Oct 2018 → Aug 2021 | nasopharyngeal carcinoma | Zhejiang Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Interleukin-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03720340 ↗ |
| Known as | IL-11 | “Mixture of 1.5 mg recombinant human interleukin -11(IL-11) and 10ml 0.9% normal saline(NS) was administered twicely to patients through respiratory tract.” NCT03720340 ↗ |
| Modality | Protein / enzyme biologic | “Mixture of 1.5 mg recombinant human interleukin -11(IL-11)” NCT03720340 ↗ |
| Route | Other | “Recombinant Human Interleukin-11 was administed through respiratory tract.” NCT03720340 ↗ |